Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)

Elise Wreven; María Soledad Ruiz de Adana; Stéphan Hardivillé; Valery Gmyr; Julie Kerr-Conte; Mikael Chetboun; Gianni Pasquetti; Nathalie Delalleau; Julien Thévenet; Anaïs Coddeville; María José Vallejo Herrera; Liad Hinden; Inmaculada Concepción Benavides Espínola; Mireia Gómez Duro; Lourdes Sanchez Salido; Francisca Linares; Francisco Javier Bermúdez-Silva; Joseph Tam; Caroline Bonner; Josephine M. Egan; Gabriel Olveira; Natalia Colomo; François Pattou; Isabel González-Mariscal

doi:10.1007/s00125-025-06372-z

Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)

Elise Wreven, María Soledad Ruiz de Adana, Stéphan Hardivillé, Valery Gmyr, Julie Kerr-Conte, Mikael Chetboun, Gianni Pasquetti, Nathalie Delalleau, Julien Thévenet, Anaïs Coddeville, María José Vallejo Herrera, Liad Hinden, Inmaculada Concepción Benavides Espínola, Mireia Gómez Duro, Lourdes Sanchez Salido, Francisca Linares, Francisco Javier Bermúdez-Silva, Joseph Tam, Caroline Bonner, Josephine M. EganGabriel Olveira, Natalia Colomo, François Pattou, Isabel González-Mariscal

School of Pharmacy

The Hebrew University of Jerusalem

Research output: Contribution to journal › Comment/debate

Abstract

Acknowledgment of funding for the project PID2021-128926OA-I00 by MICIU/AEI/10.13039/501100011033 and UE was omitted in the Funding section. The original article has been corrected.

Original language	English
Pages (from-to)	902
Number of pages	1
Journal	Diabetologia
Volume	68
Issue number	4
DOIs	https://doi.org/10.1007/s00125-025-06372-z
State	Published - Apr 2025

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s00125-025-06372-z

Fingerprint

Dive into the research topics of 'Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)'. Together they form a unique fingerprint.

Cite this

Wreven, E., de Adana, M. S. R., Hardivillé, S., Gmyr, V., Kerr-Conte, J., Chetboun, M., Pasquetti, G., Delalleau, N., Thévenet, J., Coddeville, A., Herrera, M. J. V., Hinden, L., Espínola, I. C. B., Duro, M. G., Salido, L. S., Linares, F., Bermúdez-Silva, F. J., Tam, J., Bonner, C., ... González-Mariscal, I. (2025). Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6). Diabetologia, 68(4), 902. https://doi.org/10.1007/s00125-025-06372-z

@article{b79dce0bbb30484098f5cfbb45bb90fe,

title = "Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)",

abstract = "Acknowledgment of funding for the project PID2021-128926OA-I00 by MICIU/AEI/10.13039/501100011033 and UE was omitted in the Funding section. The original article has been corrected.",

author = "Elise Wreven and {de Adana}, {Mar{\'i}a Soledad Ruiz} and St{\'e}phan Hardivill{\'e} and Valery Gmyr and Julie Kerr-Conte and Mikael Chetboun and Gianni Pasquetti and Nathalie Delalleau and Julien Th{\'e}venet and Ana{\"i}s Coddeville and Herrera, {Mar{\'i}a Jos{\'e} Vallejo} and Liad Hinden and Esp{\'i}nola, {Inmaculada Concepci{\'o}n Benavides} and Duro, {Mireia G{\'o}mez} and Salido, {Lourdes Sanchez} and Francisca Linares and Berm{\'u}dez-Silva, {Francisco Javier} and Joseph Tam and Caroline Bonner and Egan, {Josephine M.} and Gabriel Olveira and Natalia Colomo and Fran{\c c}ois Pattou and Isabel Gonz{\'a}lez-Mariscal",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = apr,

doi = "10.1007/s00125-025-06372-z",

language = "الإنجليزيّة",

volume = "68",

pages = "902",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

Wreven, E, de Adana, MSR, Hardivillé, S, Gmyr, V, Kerr-Conte, J, Chetboun, M, Pasquetti, G, Delalleau, N, Thévenet, J, Coddeville, A, Herrera, MJV, Hinden, L, Espínola, ICB, Duro, MG, Salido, LS, Linares, F, Bermúdez-Silva, FJ, Tam, J, Bonner, C, Egan, JM, Olveira, G, Colomo, N, Pattou, F & González-Mariscal, I 2025, 'Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)', Diabetologia, vol. 68, no. 4, pp. 902. https://doi.org/10.1007/s00125-025-06372-z

Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6). / Wreven, Elise; de Adana, María Soledad Ruiz; Hardivillé, Stéphan et al.
In: Diabetologia, Vol. 68, No. 4, 04.2025, p. 902.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)

AU - Wreven, Elise

AU - de Adana, María Soledad Ruiz

AU - Hardivillé, Stéphan

AU - Gmyr, Valery

AU - Kerr-Conte, Julie

AU - Chetboun, Mikael

AU - Pasquetti, Gianni

AU - Delalleau, Nathalie

AU - Thévenet, Julien

AU - Coddeville, Anaïs

AU - Herrera, María José Vallejo

AU - Hinden, Liad

AU - Espínola, Inmaculada Concepción Benavides

AU - Duro, Mireia Gómez

AU - Salido, Lourdes Sanchez

AU - Linares, Francisca

AU - Bermúdez-Silva, Francisco Javier

AU - Tam, Joseph

AU - Bonner, Caroline

AU - Egan, Josephine M.

AU - Olveira, Gabriel

AU - Colomo, Natalia

AU - Pattou, François

AU - González-Mariscal, Isabel

PY - 2025/4

Y1 - 2025/4

N2 - Acknowledgment of funding for the project PID2021-128926OA-I00 by MICIU/AEI/10.13039/501100011033 and UE was omitted in the Funding section. The original article has been corrected.

AB - Acknowledgment of funding for the project PID2021-128926OA-I00 by MICIU/AEI/10.13039/501100011033 and UE was omitted in the Funding section. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85218249304&partnerID=8YFLogxK

U2 - 10.1007/s00125-025-06372-z

DO - 10.1007/s00125-025-06372-z

M3 - تعليقَ / نقاش

C2 - 39954060

SN - 0012-186X

VL - 68

SP - 902

JO - Diabetologia

JF - Diabetologia

IS - 4

ER -

Wreven E, de Adana MSR, Hardivillé S, Gmyr V, Kerr-Conte J, Chetboun M et al. Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6). Diabetologia. 2025 Apr;68(4):902. doi: 10.1007/s00125-025-06372-z

Correction to: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans (Diabetologia, (2024), 67, 9, (1877-1896), 10.1007/s00125-024-06193-6)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this